Dermatofibroma Hypocellularity Is Associated With Patient Age: A Retrospective Study of 307 Cases
Listen to this summary
This study investigates the relationship between patient age and the prevalence of hypocellular dermatofibromas, a variant of benign fibrohistiocytic neoplasms. The authors found a significant positive correlation, indicating that the frequency of hypocellular dermatofibromas increases with age, suggesting that these lesions may undergo gradual involution and reduced cellular density over time.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of cutaneous pathology
View all →More in Dermatology
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
